IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.3090
-0.0010 (-0.32%)
At close: Jun 27, 2025, 4:00 PM
0.3199
+0.0109 (3.53%)
After-hours: Jun 27, 2025, 8:00 PM EDT
IGC Pharma Employees
IGC Pharma had 67 employees as of March 31, 2024. The number of employees increased by 6 or 9.84% compared to the previous year.
Employees
67
Change (1Y)
6
Growth (1Y)
9.84%
Revenue / Employee
$18,970
Profits / Employee
-$106,284
Market Cap
24.62M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
IGC News
- 1 day ago - IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - Accesswire
- 5 days ago - IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon - Accesswire
- 5 weeks ago - IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market - Accesswire
- 6 weeks ago - IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting - Accesswire
- 2 months ago - IGC Pharma Welcomes Strategic Investment from Advisors - Accesswire
- 2 months ago - IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs - Accesswire
- 2 months ago - IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program - Accesswire
- 3 months ago - IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health - Accesswire